Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Peres

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Blood Cancer Journal|April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy ConsortiumAimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Bone Marrow Transplantation|May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myelomaLaura B Oswald, Xiaoyin Li, Lisa M Gudenkauf, et al.
Frontiers in Physiology|November 23, 2017
A High Fat Diet during Adolescence in Male Rats Negatively Programs Reproductive and Metabolic Function Which Is Partially Ameliorated by ExerciseCarlos A Ibáñez, Rafaela P Erthal, Fernanda M Ogo, et al.
Blood Advances|January 21, 2026
Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicityLaura B Oswald, Xiaoyin Li, Carina E Ferraris, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Haematologica|July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myelomaDanai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
International Journal of Cancer|August 31, 2019
Identification of novel epithelial ovarian cancer loci in women of African ancestryAni Manichaikul, Lauren C Peres, Xin-Qun Wang, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Blood Cancer Journal|April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy ConsortiumAimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Bone Marrow Transplantation|May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myelomaLaura B Oswald, Xiaoyin Li, Lisa M Gudenkauf, et al.
Frontiers in Physiology|November 23, 2017
A High Fat Diet during Adolescence in Male Rats Negatively Programs Reproductive and Metabolic Function Which Is Partially Ameliorated by ExerciseCarlos A Ibáñez, Rafaela P Erthal, Fernanda M Ogo, et al.
Blood Advances|January 21, 2026
Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicityLaura B Oswald, Xiaoyin Li, Carina E Ferraris, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Haematologica|July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myelomaDanai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
International Journal of Cancer|August 31, 2019
Identification of novel epithelial ovarian cancer loci in women of African ancestryAni Manichaikul, Lauren C Peres, Xin-Qun Wang, et al.
Pageof 21